MeSH term
Frequency | Condition_Probility | Azathioprine/pharmacology | 3 | 30.0 |
Humans | 233 | 0.0 |
Inflammatory Bowel Diseases/*drug therapy/*genetics | 2 | 100.0 |
Methyltransferases/genetics | 7 | 41.0 |
Models, Biological | 4 | 0.0 |
P-Glycoprotein/genetics | 2 | 6.0 |
Pharmacogenetics/*methods | 3 | 17.0 |
Polymorphism, Genetic | 38 | 0.0 |
Variation (Genetics) | 8 | 0.0 |
Adolescent | 38 | 0.0 |
Adult | 75 | 0.0 |
Aged | 37 | 0.0 |
Aged, 80 and over | 11 | 0.0 |
Azathioprine/*adverse effects | 11 | 84.0 |
Child | 50 | 0.0 |
Child, Preschool | 25 | 0.0 |
Erythrocytes/*enzymology | 25 | 4.0 |
Female | 99 | 0.0 |
Great Britain | 2 | 0.0 |
Immunosuppressive Agents/*adverse effects | 10 | 25.0 |
Infant | 14 | 0.0 |
Male | 104 | 0.0 |
Methyltransferases/*analysis | 2 | 20.0 |
Middle Aged | 52 | 0.0 |
Research Support, Non-U.S. Gov't | 142 | 0.0 |
Retrospective Studies | 10 | 0.0 |
6-Mercaptopurine/*pharmacology | 3 | 75.0 |
Cell Line | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Thioguanine/*pharmacology | 2 | 40.0 |
Thionucleosides/metabolism | 2 | 100.0 |
Transfection | 3 | 0.0 |
English Abstract | 13 | 0.0 |
Genotype | 68 | 0.0 |
Methyltransferases/genetics/metabolism | 6 | 46.0 |
*Organ Transplantation | 2 | 9.0 |
*Pharmacogenetics | 10 | 20.0 |
Phenotype | 36 | 0.0 |
Base Sequence | 16 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 7 | 5.0 |
DNA Primers | 11 | 0.0 |
Kinetics | 19 | 0.0 |
Methyltransferases/*blood | 17 | 85.0 |
Radiochemistry | 3 | 27.0 |
Reproducibility of Results | 7 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Age Factors | 5 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Inflammatory Bowel Diseases/*drug therapy | 2 | 18.0 |
Leukemia, Lymphocytic, Acute/*drug therapy | 4 | 28.0 |
Methyltransferases/blood/*genetics | 7 | 100.0 |
Thionucleotides/metabolism | 5 | 38.0 |
*Gene Frequency | 5 | 0.0 |
Methyltransferases/*genetics | 53 | 52.0 |
Polymerase Chain Reaction | 24 | 0.0 |
*Alleles | 7 | 0.0 |
Asian Continental Ancestry Group/*genetics | 4 | 1.0 |
DNA Mutational Analysis | 5 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 10 | 3.0 |
Gene Frequency | 20 | 0.0 |
Mutation | 19 | 0.0 |
Polymorphism, Restriction Fragment Length | 12 | 0.0 |
Azathioprine/therapeutic use | 5 | 12.0 |
Comparative Study | 33 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Immunosuppressive Agents/therapeutic use | 5 | 2.0 |
Methylation | 21 | 3.0 |
Methyltransferases/genetics/*metabolism | 9 | 30.0 |
Spain | 2 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Drug Administration Schedule | 8 | 0.0 |
Reference Values | 4 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Treatment Outcome | 14 | 0.0 |
Inflammatory Bowel Diseases/*drug therapy/*metabolism | 2 | 100.0 |
Methyltransferases/*metabolism | 15 | 22.0 |
Enzyme Stability | 3 | 1.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Leukocyte Count | 6 | 0.0 |
Thioguanine/metabolism | 3 | 75.0 |
6-Mercaptopurine/*analogs & derivatives/blood | 2 | 100.0 |
Azathioprine/pharmacokinetics | 2 | 100.0 |
Linear Models | 4 | 0.0 |
Thioguanine/blood | 4 | 100.0 |
6-Mercaptopurine/metabolism/therapeutic use | 2 | 100.0 |
Drug Interactions | 7 | 0.0 |
Drug Monitoring/*methods | 2 | 10.0 |
Alleles | 31 | 0.0 |
Methyltransferases/*genetics/metabolism | 23 | 60.0 |
*Mutation | 4 | 0.0 |
Norway/ethnology | 2 | 66.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Chromatography, High Pressure Liquid | 11 | 0.0 |
Linkage Disequilibrium | 4 | 0.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Portugal | 3 | 4.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
6-Mercaptopurine/metabolism | 7 | 100.0 |
Azathioprine/*therapeutic use | 8 | 57.0 |
Immunosuppressive Agents/*therapeutic use | 7 | 5.0 |
Methyltransferases/metabolism | 7 | 22.0 |
Prospective Studies | 10 | 0.0 |
Diagnostic Errors | 2 | 2.0 |
Methyltransferases/deficiency/*genetics | 2 | 50.0 |
Animals | 19 | 0.0 |
Biotransformation | 6 | 1.0 |
Mice | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 66 | 0.0 |
Tumor Cells, Cultured | 4 | 0.0 |
*Genetics, Population | 3 | 0.0 |
Japan | 4 | 0.0 |
*Kidney Transplantation | 2 | 0.0 |
Italy | 2 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Methyltransferases/blood/genetics/*metabolism | 2 | 100.0 |
European Continental Ancestry Group/genetics | 10 | 1.0 |
*Polymorphism, Genetic | 26 | 0.0 |
Structure-Activity Relationship | 5 | 0.0 |
Liver/drug effects/*enzymology | 2 | 5.0 |
6-Mercaptopurine/*adverse effects | 4 | 100.0 |
Antimetabolites, Antineoplastic/*adverse effects | 2 | 28.0 |
Methyltransferases/*deficiency/*genetics/metabolism | 2 | 100.0 |
Risk Factors | 3 | 0.0 |
Methyltransferases/*blood/genetics | 8 | 100.0 |
Substrate Specificity | 8 | 0.0 |
6-Mercaptopurine/adverse effects/therapeutic use | 5 | 100.0 |
Immunosuppressive Agents/adverse effects/therapeutic use | 3 | 42.0 |
6-Mercaptopurine/adverse effects | 2 | 66.0 |
Point Mutation | 6 | 0.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Pharmacogenetics | 9 | 8.0 |
Acute Disease | 4 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Erythrocytes/enzymology | 20 | 5.0 |
Safety | 2 | 1.0 |
China/ethnology | 4 | 2.0 |
Molecular Sequence Data | 15 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Bone Marrow/*drug effects/pathology | 2 | 20.0 |
Methyltransferases/*deficiency | 6 | 40.0 |
Minisatellite Repeats/genetics | 2 | 4.0 |
Open Reading Frames | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 5 | 0.0 |
Species Specificity | 2 | 0.0 |
Methyltransferases/blood/*metabolism | 2 | 66.0 |
*Phenotype | 2 | 0.0 |
6-Mercaptopurine/*adverse effects/therapeutic use | 3 | 100.0 |
Azathioprine/*adverse effects/therapeutic use | 5 | 100.0 |
Colitis, Ulcerative/*drug therapy | 2 | 50.0 |
Crohn Disease/*drug therapy | 2 | 18.0 |
Immunosuppressive Agents/*adverse effects/therapeutic use | 4 | 30.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Pharmacogenetics/methods | 3 | 30.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
Azathioprine/*administration & dosage | 3 | 75.0 |
Homozygote | 9 | 0.0 |
Immunosuppressive Agents/*administration & dosage | 3 | 10.0 |
Leukopenia/chemically induced | 3 | 16.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Thrombocytopenia/chemically induced | 2 | 10.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Asia | 2 | 2.0 |
Disease-Free Survival | 2 | 0.0 |
Ethnic Groups/genetics | 3 | 1.0 |
France | 3 | 1.0 |
Risk | 3 | 0.0 |
Pemphigoid, Bullous/drug therapy | 2 | 100.0 |
Neutropenia/chemically induced | 4 | 10.0 |
Genetic Screening/*methods | 3 | 2.0 |
Leukemia, Lymphocytic, Acute/enzymology/genetics | 2 | 100.0 |
Time Factors | 8 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Methyltransferases/deficiency/*genetics/metabolism | 3 | 75.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 5 | 1.0 |
COS Cells | 5 | 0.0 |
In Vitro | 5 | 0.0 |
Rabbits | 5 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
S-Adenosylmethionine/pharmacology | 3 | 27.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Guanine Nucleotides/metabolism | 3 | 15.0 |
Heterozygote | 11 | 0.0 |
Mutation/genetics | 3 | 0.0 |
6-Mercaptopurine/administration & dosage/*adverse effects | 2 | 100.0 |
Quality Control | 2 | 1.0 |
*Minisatellite Repeats | 2 | 2.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
6-Mercaptopurine/therapeutic use | 2 | 50.0 |
Case-Control Studies | 2 | 0.0 |
Nucleotidases/*metabolism | 2 | 66.0 |
Pilot Projects | 3 | 0.0 |
Administration, Oral | 5 | 0.0 |
Methotrexate/administration & dosage | 4 | 4.0 |
Prognosis | 4 | 0.0 |
Remission Induction | 6 | 1.0 |
Amino Acid Sequence | 7 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Antimetabolites, Antineoplastic/*therapeutic use | 2 | 5.0 |
Methotrexate/therapeutic use | 2 | 3.0 |
Neoplasms/*drug therapy | 2 | 1.0 |
DNA/analysis/genetics | 2 | 1.0 |
Neoplasms/*drug therapy/*enzymology/genetics | 2 | 50.0 |
Colitis, Ulcerative/*drug therapy/genetics | 3 | 100.0 |
Thionucleotides/blood | 5 | 100.0 |
Risk Assessment | 4 | 0.0 |
Arthritis, Rheumatoid/*drug therapy/*enzymology | 3 | 100.0 |
Longitudinal Studies | 2 | 0.0 |
6-Mercaptopurine/*pharmacokinetics | 2 | 100.0 |
Antimetabolites, Antineoplastic/*pharmacokinetics | 2 | 25.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
Hypoxanthine Phosphoribosyltransferase/metabolism | 3 | 25.0 |
*Drug Monitoring | 3 | 15.0 |
Blotting, Western | 3 | 0.0 |
Point Mutation/*genetics | 2 | 0.0 |
S-Adenosylmethionine/metabolism | 3 | 15.0 |
6-Mercaptopurine/*metabolism | 4 | 100.0 |
Cloning, Molecular | 8 | 0.0 |
Methyltransferases/*genetics/*metabolism | 6 | 66.0 |
Exons | 4 | 0.0 |
Pedigree | 2 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Methyltransferases/blood | 4 | 66.0 |
Regression Analysis | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Cytarabine/administration & dosage | 2 | 2.0 |
Logistic Models | 2 | 0.0 |
Bone Marrow/*drug effects | 3 | 11.0 |
*Point Mutation | 2 | 0.0 |
Guanine Nucleotides/blood | 4 | 100.0 |
Korea | 3 | 1.0 |
Norway | 2 | 1.0 |
United States | 4 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Azathioprine/*metabolism | 2 | 100.0 |
Azathioprine/adverse effects/*therapeutic use | 6 | 60.0 |
Bone Marrow/drug effects | 3 | 4.0 |
Immunosuppressive Agents/adverse effects/*therapeutic use | 5 | 27.0 |
Mice, Inbred Strains | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Sex Factors | 6 | 0.0 |
Purine-Nucleoside Phosphorylase/metabolism | 2 | 16.0 |
Fetal Blood/enzymology | 2 | 13.0 |
Infant, Newborn | 6 | 0.0 |
Kidney/*enzymology | 6 | 8.0 |
Liver/*enzymology | 4 | 0.0 |
Methyltransferases/*antagonists & inhibitors | 2 | 15.0 |
Recombinant Proteins/antagonists & inhibitors | 2 | 4.0 |
Chromosome Mapping | 3 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
*Sex Characteristics | 2 | 1.0 |
Methyltransferases/*blood/*genetics | 2 | 100.0 |
Bone Marrow Diseases/chemically induced | 2 | 40.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Kidney Transplantation/*immunology | 2 | 0.0 |
Biological Markers/blood | 5 | 0.0 |
Thioguanine/*metabolism | 2 | 100.0 |
Treatment Failure | 2 | 0.0 |
Gallic Acid/analogs & derivatives/pharmacology | 4 | 25.0 |
Catalysis | 2 | 0.0 |
Subcellular Fractions/enzymology | 3 | 3.0 |
Purines/*metabolism | 2 | 9.0 |
Azathioprine/adverse effects/therapeutic use | 3 | 100.0 |
Escherichia coli/enzymology | 2 | 3.0 |
Chromatography, Ion Exchange | 3 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Methyltransferases/antagonists & inhibitors/*metabolism | 3 | 33.0 |
Microsomes, Liver/enzymology | 2 | 0.0 |
6-Mercaptopurine/*therapeutic use | 4 | 100.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Ethnic Groups | 2 | 0.0 |
6-Mercaptopurine/pharmacology | 3 | 100.0 |
Prednisolone/therapeutic use | 2 | 2.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Diagnosis, Differential | 2 | 0.0 |
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use | 2 | 33.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Antimetabolites/adverse effects/metabolism/*therapeutic use | 2 | 100.0 |
Azathioprine/*administration & dosage/adverse effects | 2 | 100.0 |
Cercopithecus aethiops | 2 | 0.0 |
Inflammatory Bowel Diseases/*drug therapy/enzymology | 2 | 100.0 |
Benzoates/*pharmacology | 2 | 18.0 |
Kidney/enzymology | 5 | 3.0 |
Models, Chemical | 2 | 0.0 |
Sulfhydryl Compounds/*metabolism | 3 | 15.0 |
Thiadiazoles/*metabolism | 2 | 100.0 |
Arylamine N-Acetyltransferase/genetics | 2 | 3.0 |
